Bicara Stock Soars 9% After Results — Its Cash Runway Extends Into Early 2029
The cancer-drug developer's quarterly loss widened as trial and staffing costs rose, with pivotal trial results expected in mid-2027.
Bicara Therapeutics, which develops experimental treatments for solid tumors, soared 8.90% to $9.42 in Monday trading, as of 11:45 a.m. ET, adding $51 million in market value after its results. On Monday's earnings call, management discussed shifting launch assumptions toward survival evidence as rival competition intensifies; the company expects its cash to last into the first half of 2029.
A Rebound After A 48% Slide
BCAX shares were on pace for their second gain of 7% or more this month in Monday trading. Bicara's market value stood at $623.35 million in that session.
The rebound follows a sharp retreat. At Friday's close, Bicara was down 49% year-to-date, while the S&P 500 had gained 8%. The stock had lost 48% over the previous month.
Trial Costs Widen The Loss
Bicara's third-quarter net loss reached $71.2 million, compared with $36.3 million a year earlier, according to Monday's SEC filing. Higher trial and staffing costs were the primary factors accompanying the wider loss.
Cash and investments totaled $442.3 million, against $414.8 million at year-end 2025. Management projects that funding will cover operations into the first half of 2029.
The company's earlier quarterly report recorded a $55.4 million loss for the period ended June 30.
Ficerafusp Alfa's Head And Neck Test
Bicara reported substantial enrollment in its pivotal head and neck cancer trial in Monday's business update. The ongoing global mid- to late-stage study tests its lead candidate, ficerafusp alfa, alongside pembrolizumab.
Ficerafusp alfa pairs a cancer-targeting antibody with a component intended to block signals that promote tumor growth and suppress immune activity. Bicara also studies the candidate in colorectal cancer and other solid tumors.
The company remains a clinical-stage drug developer: its treatments are being tested in patients through trials rather than sold commercially.
Bicara expects the pivotal head and neck study's initial interim analysis results in mid-2027.
Sources
- Bicara Therapeutics Q3 2026 Earnings Call Transcript — benzinga.com
- Bicara Therapeutics GAAP EPS of -$1.04 misses by $0.22 (BCAX:NASDAQ) | Seeking Alpha — seekingalpha.com
- Bicara Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- The company's filing (Bicara Therapeutics) — SEC filing
- Bicara Therapeutics — Form 10-Q for the quarter ended 2026-06-30 (quarterly results) — SEC EDGAR